About Retatrutide Risk

Retatrutide Risk is an independent editorial project. It exists because the search results for retatrutide are dominated by sellers and forums, while the primary evidence sits behind journal paywalls and in trial registries that few people read.

What we publish

Plain-language articles on the risks, side effects, trial dosing, results and regulatory status of retatrutide, an investigational GIP, GLP-1 and glucagon receptor agonist developed by Eli Lilly. Each article opens with a short list of key facts, uses tables for the numbers, and closes with a list of sources.

How we work

• Every figure is traced to a peer-reviewed publication, a ClinicalTrials.gov registration, an FDA prescribing document or a dated company announcement. The source is cited on the same page, with a clickable DOI or URL.
• Every DOI is checked against the CrossRef registry before it is published, and every trial identifier is checked against the ClinicalTrials.gov record. If a reference cannot be verified, it is not used.
• Company press releases are labelled as such and are never treated as equivalent to a peer-reviewed paper.
• We state what is not known. Where the trials have not measured something, the article says so rather than filling the gap with forum anecdotes.
• We do not publish dosing recommendations. Doses are reported only as they were administered in registered clinical trials.

What we do not do

We do not sell retatrutide or any other product, we do not run advertising, and we do not use analytics or cookies. The bar at the top of every page links to a research-use supplier; it is the only commercial link on the site and it is not a recommendation to use the compound. Our editorial policy sets this out in full.

Contact

Corrections, missing sources or questions: hello@retatrutiderisk.com. We answer correction requests first.

Articles are signed “Retatrutide Risk editorial team”. Nobody on the team is a licensed physician and nothing on this site is medical advice.